StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III
Insilico Medicine, an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants, has offered investors an upbeat revenue and profit forecast…
Read the full articleYou might also wanna read
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore
Insilico Medicine and Bora Pharmaceuticals announce AI-driven drug discovery partnership
Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target st
news-medical.net·1d agoInsilico + CMS $1.2B CNS AI Drug Deal Explained (July 2026)
Insilico Medicine and China Medical System expanded their AI drug discovery collaboration July 12, 2026 with ~1.2B RMB milestones. What it i
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 13, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generativ
Insilico's AI-discovered lung fibrosis drug enters Phase III
Rentosertib will test whether Insilico's end-to-end AI drug discovery thesis can survive late-stage clinical scrutiny.
Takeda signs $600M AI drug discovery deal with Insilico
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japan
Comments
Sign in to join the conversation.
No comments yet. Be the first.